John M. Evans

CEO John M. Evans sold 50,000 shares ($1.7M) in 4 transactions; holdings remain 1,047,205 shares via scheduled 10b5-1 plan adopted May 2025.

John M. Evans, CEO of Beam Therapeutics, executed 4 separate sales totaling 50,000 shares for $1,745,037.20 at a blended average price of $34.90 per share on June 29–30, 2026, pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-05-16. The sales represent a -4.6% reduction of his pre-transaction holdings; he retains 1,047,205 non-derivative shares and derivative holdings totaling 436,617 shares (9 + 230,804 + 205,804 option shares), so his position remains substantial. His prior sales at BEAM over the last six months posted strong post-sale price appreciation (ranging from +24.9% to +39.6% over 30 days and +39.6% to +55.6% over 90 days on three recent April and March 2026 sales), suggesting he has consistently sold into strength; the current price of $33.48 sits -9.2% below the 52-week high of $36.88. The company remains unprofitable (net income $-94.3M over the latest full year) despite strong revenue growth of +120.0%, and recent quarterly revenue stands at $31.7M. Because this sale is scheduled under a 10b5-1 plan rather than discretionary, it does not reflect a timing signal or change in conviction, but the cumulative pattern of scheduled sales by the CEO warrants monitoring given the company's ongoing unprofitability and the insider's historical tendency to sell into rallies.

CEO Evans sold 30,078 shares at $24.58 on 2026-04-01; stock down 31.6% from 52-week high and trading 0.6% below sale price.

CEO John M. Evans sold 30,078 shares (30.1K shares) of BEAM at $24.58 on 2026-04-01 for $739,317.24, reducing his holdings by 2.8% to 1,047,205 shares. The stock is currently at $24.23—a slight 0.6% discount to the sale price—and down 31.6% from its 52-week high of $35.41. At the same ticker, his cross-ticker track record shows a 70.00% well-timed rate on prior sells, but at BEAM specifically, outcomes on his prior 5 trades remain inconclusive: the most recent BEAM sales (2026-03-31 and 2026-03-30) have no measurable outcomes yet, earlier January 2026 sales showed mixed 30-day returns (ranging from -2.5% to +0.7%), and 0 of 0 prior BEAM sales were well-timed at the 90-day mark. Fundamentally, BEAM is an unprofitable biotech company with $9.7M in latest quarterly revenue, a $-112.7M net loss, yet 120.0% annual revenue growth; the $2.5B market cap reflects deep pre-commercial positioning. This sale occurs in the context of recent price weakness and multiple consecutive sales by the same insider within days.

BEAM CEO Evans sells 50,000 shares in 2 transactions for $1,128,315.00; stock down -15.6% (30d), -12.6% (90d)

CEO John M. Evans sold 50,000 shares (4.4% of pre-transaction holdings) across two separate transactions on 2026-03-30 and 2026-03-31 at a blended average price of $22.57, raising $1,128,315.00. The stock has declined -15.6% in the 30 days and -12.6% in the 90 days since these sales, with current price at $24.22 still -31.6% from the 52-week high of $35.41. Evans' cross-ticker track record shows a 70.00% well-timed rate on 15 prior sells (average 90d return -9.6%), indicating a demonstrated pattern of selling before declines. His prior trades at BEAM specifically show mixed recent outcomes (5 prior trades from late January through early April 2026), though measurable 90-day results are not yet available for most. The company remains unprofitable with net income of $-112,728,000.00 against quarterly revenue of $9,698,000.00, though annual revenue growth stands at +120.0% year-over-year.

CEO Evans sells 50,000 shares for $1.4M at $28.87 avg; stock down -21.2% from 52-week high

John M. Evans, CEO of Beam Therapeutics, executed 4 separate sales totaling 50,000 shares for $1,443,528.45 across January 29–30, 2026, at a blended average price of $28.87. The sales reduced his holdings from 1,036,667 shares to 986,667 shares (-4.8%). The current stock price of $27.92 sits -21.2% from the 52-week high of $35.41, indicating the stock has declined materially since his transaction prices. Beam's fundamentals show severe deterioration: annual revenue contracted -83.2% year-over-year to $9,698,000.00 in the latest quarter, net income was $-112,728,000.00, and the company remains unprofitable. Evans' prior 5 trades at BEAM show mixed timing: 3 of 5 prior sales were well-timed at the 90-day mark, though his cross-ticker track record across 10 prior sales shows a 90d well-timed rate of 70.00% with an average 90-day return of -9.6%—indicating better timing discipline historically. The combination of large shareholder reduction amid deteriorating revenue trends and current price weakness warrants investor scrutiny of the company's operational trajectory.

CEO Evans sells 50,000 BEAM shares for $1,228,322.50; prior trades at this ticker 4-of-5 well-timed at 90d; stock +37.3% in 30d but fundamentals deteriorating.

John M. Evans (CEO) executed 2 separate sales totaling 50,000 shares for $1,228,322.50 on October 1–2, 2025, at an average price of $24.57, reducing holdings by 4.8% to 986,667 shares. His timing record at BEAM is notably strong: 4 of 5 prior sales at this ticker were well-timed at the 90-day mark, suggesting pattern-based predictive value. However, context complicates the signal: BEAM's stock has surged +37.3% over the prior 30 days and stands only -24.5% below its 52-week high, yet the company posted $-102,291,000.00 net income in the latest full fiscal year, annual revenue collapsed -83.2%, and quarterly revenue stood at only $8,466,000.00. The sale occurs during a sharp rally in a fundamentally deteriorating business, which may reflect opportunistic liquidity-raising rather than forward-looking concern. Given strong prior sell-timing at this ticker but elevated price relative to business trajectory, this warrants monitoring of whether the 90-day pattern holds.

CEO Evans sells 30,663 BEAM shares at $18.35; stock now at $16.46, down 51.7% from 52-week high of $34.09

John M. Evans, CEO, sold 30,663 shares of Beam Therapeutics at $18.35 on 2025-04-01, reducing his holdings from 1,016,912 shares to 986,249 shares. The sale occurred at a price significantly above the current market price of $16.46, which stands 51.7% below the 52-week high of $34.09 and represents a 37.8% decline over the prior 30 days. Beam's fundamentals show acute deterioration: revenue contracted 83.2% year-over-year to $14,269,000.00, the company posted a net loss of $96,668,000.00 in the latest quarter, and remains unprofitable on a full-year basis, with a market cap of only $1,377,509,335.70. At his same-ticker prior trades at BEAM, Evans achieved well-timed outcomes on 2 of 3 measurable 90-day periods, with mixed near-term results on his two January 2025 sales; this April sale must be interpreted alongside the severe operational contraction and steep price deterioration already underway in the stock.

CEO Evans sells 30,000 BEAM shares for $802.5K; stock down 43.2% from 52-week high despite +520.0% revenue growth

Evans John M., CEO of Beam Therapeutics, executed 2 separate sales totaling 30,000 shares for $802,483.82, reducing his holdings from 938.7K to 908.7K shares (-3.2%). His same-ticker selling history at BEAM shows mixed timing—4 of 5 prior sells had negative 90-day returns (well-timed exits before declines), yet this transaction follows a context where the stock is currently down 43.2% from its 52-week high of $45.07, despite the company reporting annual revenue growth of +520.0%. The company remains unprofitable (latest net income: $-96.7M against quarterly revenue of $14.3M), creating a valuation disconnect: exceptional topline growth has not translated to profitability or stock appreciation. Evans' prior transactions at this ticker show he has historically sold near local peaks before subsequent declines, suggesting pattern recognition or informed positioning, though his cross-ticker well-timed rate of 80.00% is weaker at the single-ticker level.

CEO John M. Evans sold 60,000 shares of BEAM at $24.60 on 2024-09-30; stock now -47.9% from 52-week high of $45.07.

John M. Evans, the CEO, executed a 60,000-share sale at $24.60, reducing his holdings from 998,659 to 938,659 shares. The stock has since declined to $23.50, placing it -47.9% below its 52-week high and -11.9% down over the trailing 30 days. His prior trades at Beam show a consistent pattern: four of four prior sells were well-timed at the 90-day mark, with 90-day returns averaging -15.0% after those sales—indicating he has successfully sold before price declines. The company remains unprofitable with a net loss of $91.1M against quarterly revenue of $11.8M, yet posted 520% revenue growth year-over-year. This sell aligns with his historical skill in exiting before downturns at this ticker, occurring as the stock moves further below his transaction price and the company approaches equity capital constraints typical of pre-profitability biotech firms.

CEO Evans sells 60,000 BEAM shares at $24.50; stock down -48.0% from 52-week high, company unprofitable with $-98.7M net loss.

CEO John M. Evans sold 60,000 shares (60.0K shares) at $24.50 on 2024-06-27, reducing his stake to 998,343 shares (998.3K shares). The sale occurred when BEAM was trading -48.0% below its 52-week high of $45.07, and the company remains unprofitable with annual net income of $-98.7M against quarterly revenue of $7.4M. At the same-ticker level, Evans's prior two measurable sells (2024-03-28 and 2024-01-31) both delivered negative 90-day returns of -26.6% and -16.2% respectively, establishing a pattern of well-timed exits. The stock has declined -29.1% over 90 days and -1.1% over 30 days from the sale date, consistent with the downward trajectory that has characterized his recent BEAM transactions. An investor should monitor whether this latest sale aligns with the insider's demonstrated ability to exit prior to further depreciation, particularly given the company's ongoing operating losses.